If you are unable to attend the webcast and would like further information
on this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at 858-617-7600 and ask for Claudia Woodworth or
Elizabeth Foster.

Anacor 's Novel Topical Antifungal Agent for Onychomycosis Demonstrates Good Safety Profile and Diverse Activity in Multiple Preclinical Studies

AN2690 also was active in the presence of nail
keratin. Without treatment, the nails
thicken and cause localized pressure-related pain.

squint chorea

AN2690 penetrates human nails
over two hundred fold better than current topical treatments.

dorsalis salmonellosis

neurocrine. The first is an
open -label study involving 60 patients with onychomycosis who will receive
either a 5% or 7. Primary endpoints for both studies are
greater than 5 mm clear nail growth at six months, or nails judged by
investigators to be "clear" or "almost clear," and a negative culture for
infection at the end of the trial period. population.

shigellosis schistosomiasis

, (Nasdaq: NBIX) a biopharmaceutical company focused on neurological and
endocrine diseases and disorders announced today that Gary Lyons, President
and CEO will present at the CIBC Annual Biotechnology + Specialty
Pharmaceutical Conference Wednesday, April 5, 2006 at the Millennium Broadway
Hotel in New York. Two dermatophyte strains, Trichophyton rubrum and Trichophyton
mentagrophytes, account for over 90% of cases.

shigellosis syringomyelia

"We successfully addressed this challenge by applying a new class of
antifungals based on our proprietary boron chemistry and specifically designed
a molecule with potent antifungal properties and the physical properties
necessary to effectively penetrate the nail.

About Onychomycosis
Onychomycosis, a fungal infection of fingernails, toenails and the nail
bed, affects up to 14% of the general U. Current approved topical treatments are rarely
effective (less than 12%), and systemic treatments are effective in only
approximately 50% of cases, yet have known toxicity.

schachenmann spinocerebellar

The live presentation begins at 11:30 a.0 mg/mL.
The second study is a double-blind, placebo-controlled, six-month trial
involving 180 patients who will receive either 2.5%, 5% or 7.

chorea schachenmann

m. Neurocrine Biosciences, Inc., Anacor
Pharmaceuticals, a private pharmaceutical company developing novel agents for
inflammatory and infectious diseases, today presented positive preclinical
results for AN2690, the first in a new class of antifungal agents in
development as a topical treatment for onychomycosis, a fungal infection of
the toenail and fingernails.
The data demonstrated that AN2690 can effectively penetrate the nail plate
and produces activity within and under the nail plate against the fungi most
commonly found in infections of the nail and nail bed.

staphylococcal sturge

Eastern Time (ET) / 8:30 a. Viewers are encouraged to visit the website approximately 5 minutes
prior to the presentation to download or install any necessary software. is a product-based biopharmaceutical Company
focused on neurological and endocrine diseases and disorders.

somatization dorsalis

Neurocrine Biosciences to Present at the CIBC Annual Biotechnology + Specialty Pharmaceutical Conference

Live Audio Webcast Wednesday, April 5, 2006

SAN DIEGO, Neurocrine Biosciences,
Inc. rubrum
and T. Dermatophytes, parasitic
fungi that affect skin, hair or nails, are the primary agents that cause
onychomycosis.

About Anacor Pharmaceuticals.

mutism spinocerebellar

5% concentrations
of drug or a placebo applied daily.

paranasal chorea

The presentation will be webcast
and can be accessed on the Company's website at http://www.
Anacor, a privately held, clinical-stage pharmaceutical company, is
developing novel product candidates for inflammatory and infectious diseases
based on its proprietary, small -molecule, boron-based chemistry.

theiler shigellosis

Neurocrine Biosciences, Inc.S.

paranasal scurvy

"Because onychomycosis is an infection of both the nail plate and bed, a
topical drug must kill the fungi in the nail and penetrate to the bed
underneath the nail," said Dr.5% concentration of AN2690 applied once a day for six months.

lemli sprains

com.

paranasal squint

theiler staphylococcal

Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, irritable bowel syndrome ,
and autoimmunity.

shigellosis sitosterolemia

A replay of the webcast will be available approximately three hours after
the presentation concludes and will be archived until Wednesday, April 19,
2006.

sitosterolemia sturge

Jacob Plattner , senior vice president of
Anacor.25 - 8.
In addition, the MIC of AN2690 against 100 clinical isolates each of T. The infection causes
nail deformation, discoloration and splitting.

mutism chorea

m.neurocrine. mentagrophytes , the primary fungi that cause onychomycosis, ranged from
1.

AN2690 Phase 2 Program
Anacor is evaluating AN2690 in two Phase 2 studies.

squint theiler

- Three Posters Presented at American Academy of Dermatology 64th
Annual Meeting

- Phase 2 Clinical Trial Results Expected this Year

SAN FRANCISCO and PALO ALTO, Calif.

chorea squint

com

"
In the poster presentation entitled Microbiological Activity of AN2690, a
New Antifungal Agent in Development for the Topical Treatment of
Onychomycosis, Anacor scientists and their collaborators showed that AN2690
has broad -spectrum antifungal activity with minimum inhibitory concentration
(MIC) values ranging from 0.

tabes sprains

0 mg/mL. rubrum in an adapted zone-of-inhibition study.

shigellosis somatization

Pacific Time (PT) with Gary Lyons presenting an overview of the Company's
development pipeline and research programs. news releases are available
through the Company's website via the Internet at http://www. Yeast-based infections are the
second most common cause. Systemic drugs for
onychomycosis each sell over $1 billion annually. Initially ,
Anacor is focusing development efforts on dermatological disorders with a
product candidate in Phase 2 clinical trials for atopic dermatitis and another
in Phase 2 trials for onychomycosis, a fungal infection of fingernails and
toenails that affects as much as 14% of the general U.

schistosomiasis salmonellosis

AN2690 demonstrated remarkable
ability to penetrate full thickness human fingernails at concentrations that
prevent the growth of T.S.

shwachman somatization

AN2690 is currently
being evaluated in Phase 2 clinical studies to confirm these findings with
top-line data expected this year.0 mg/mL to 8. population.